Edesa Biotech Valuation
| EDSA Stock | USD 4.47 0.09 2.05% |
At this time, the firm appears to be undervalued. Edesa Biotech shows a prevailing Real Value of $16.3 per share. The current price of the firm is $4.47. Our model computes the value of Edesa Biotech from reviewing the firm fundamentals such as Shares Owned By Institutions of 10.74 %, shares owned by insiders of 28.35 %, and Current Valuation of 9.7 M as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise taking in undervalued instruments and trading overvalued instruments since, at some point, asset prices and their ongoing real values will submerge. Key fundamental drivers impacting Edesa Biotech's valuation include:
Price Book 2.4649 | Enterprise Value 9.7 M | Enterprise Value Ebitda (1.31) | Price Sales 120.5 K | Forward PE 0.1716 |
Undervalued
Today
Please note that Edesa Biotech's price fluctuation is somewhat reliable at this time. Calculation of the real value of Edesa Biotech is based on 3 months time horizon. Increasing Edesa Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Edesa Biotech is useful when determining the fair value of the Edesa stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Edesa Biotech. Since Edesa Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Edesa Stock. However, Edesa Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.47 | Real 16.3 | Target 52.33 | Hype 4.47 |
The real value of Edesa Stock, also known as its intrinsic value, is the underlying worth of Edesa Biotech Company, which is reflected in its stock price. It is based on Edesa Biotech's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Edesa Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Edesa Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Edesa Biotech helps investors to forecast how Edesa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Edesa Biotech more accurately as focusing exclusively on Edesa Biotech's fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Edesa Biotech's intrinsic value based on its ongoing forecasts of Edesa Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Edesa Biotech's closest peers. When choosing an evaluation method for Edesa Biotech, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Edesa Biotech Investments |
|
Edesa Valuation Trend
Knowing Edesa Biotech's actual value is paramount for traders to make sound investment determinations. Edesa Biotech's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Edesa Biotech's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Edesa Biotech's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Edesa Market Cap
Edesa Biotech is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is currently estimated at about 709.55 Million. Edesa Biotech claims roughly 14.09 Million in market capitalization contributing just under 2% to equities under Health Care industry.Edesa Biotech Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Edesa Biotech's current stock value. Our valuation model uses many indicators to compare Edesa Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Edesa Biotech competition to find correlations between indicators driving Edesa Biotech's intrinsic value. More Info.Edesa Biotech is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies . The current year's Price To Book Ratio is expected to grow to 115.07. Comparative valuation analysis is a catch-all model that can be used if you cannot value Edesa Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Edesa Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edesa Biotech's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Edesa Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Edesa Biotech and how it compares across the competition.
About Edesa Biotech Valuation
The stock valuation mechanism determines the current worth of Edesa Biotech on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Edesa Biotech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Edesa Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Edesa Biotech's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Edesa Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Edesa Biotech. We calculate exposure to Edesa Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Edesa Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -165.1 K | -156.9 K | |
| Pretax Profit Margin | (26.00) | (27.30) | |
| Operating Profit Margin | (17.67) | (18.56) | |
| Net Loss | (26.08) | (27.38) | |
| Gross Profit Margin | (0.94) | (0.89) |
8 Steps to conduct Edesa Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Edesa Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Edesa Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Edesa Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Edesa Biotech's revenue streams: Identify Edesa Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Edesa Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Edesa Biotech's growth potential: Evaluate Edesa Biotech's management, business model, and growth potential.
- Determine Edesa Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Edesa Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Edesa Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Edesa Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 20 M | |
| Forward Price Earnings | 0.1716 |
Edesa Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Edesa Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Edesa we look at many different elements of the entity such as Edesa's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Edesa Biotech's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Edesa Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Edesa Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Edesa Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Edesa Biotech's worth.When determining whether Edesa Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Edesa Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Edesa Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Edesa Biotech Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.